This is a working overview of Certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-21. Anything still debated is marked as such rather than presented as settled.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
McQuillan, Discharge residues from cartridge-operated industrial tools, J. Forens. Sci. Soc. 24 (1984) 495–508. J.S. Wallace, Chemical Analysis of Firearms, Ammunition, and Gunshot Residue, (2008) CRC Press LLC. G.M. Wolten, R.S. Nesbitt, A.R. Calloway, G.L. Loper, P.F. Jones, Particle analysis for the detection of gunshot residue. I: Scanning electron microscopy/energy dispersive X-ray characterisation of hand deposits from firing, J. Forens. Sci. 24 (1979) 409–422. G.M. Wolten, R.S. Nesbitt, A.R. Calloway, G.L. Loper, Particle analysis for the detection of gunshot residue. II: occupational and environmental particles, J. Forens. Sci. 24 (1979) 423–430. G.M. Wolten, R.S. Nesbitt, A.R. Calloway, Particle analysis for the detection of gunshot residue. III: the case record, J. Forens. Sci. 24 (1979) 864–869.
=== Breast cancer === In normal tissue, STAT5a mediates effects of prolactin in mammary glands. In breast cancer, STAT5a signaling is important for maintain tumor differentiation and suppressing disease progression. Studies originally showed a correlation between high STAT5a expression and tumor differentiation in mice models, but histopathological analysis of human breast cancer tissue has shown a different trend. It was shown that low nuclear levels of STAT5a was associated with unfavorable clinical outcomes and cancer progression independent of STAT5b expression. High STAT5a was suggested to be an inhibitor of invasion and metastasis and therefore an indicator of favorable clinical outcomes. Because of these trends, it has been proposed as a predictor of response to therapies such as anti-estrogen treatment.
European Union law is a system of supranational laws operating within the 27 member states of the European Union (EU). Originally referred to as Community law, it has grown over time since the 1952 founding of the European Coal and Steel Community, to promote peace, social justice, a social market economy with full employment, and environmental protection. The Treaties of the European Union agreed to by member states form its constitutional structure. EU law is interpreted by, and EU case law is created by, the judicial branch, known collectively as the Court of Justice of the European Union. Legal Acts of the EU are created by a variety of EU legislative procedures involving the popularly elected European Parliament, the Council of the European Union (which represents member governments), the European Commission (a cabinet which is elected jointly by the Council and Parliament) and sometimes the European Council (composed of heads of state). Only the Commission has the right to propose legislation. Legal acts include regulations, which are automatically enforceable in all member states; directives, which typically become effective by transposition into national law; decisions on specific economic matters such as mergers or prices which are binding on the parties concerned, and non-binding recommendations and opinions. Treaties, regulations, and decisions have direct effect – they become binding without further action, and can be relied upon in lawsuits. EU laws, especially Directives, also have an indirect effect, constraining judicial interpretation of national laws.
=== Class II === The heme group in class II cytochrome c proteins is attached to a C-terminal binding motif. The structural fold of class II c-type cytochromes contains a four α-helix bundle with the covalently attached heme group at its core. Representatives of class II are the high-spin cytochrome c' and a number of low-spin cytochromes c, e.g. cyt c556. The cyt c' are capable of binding such ligands as CO, NO or CN−, albeit with rate and equilibrium constants 100 to 1,000,000-fold smaller than other high-spin hemeproteins. This, coupled with its relatively low redox potential, makes it unlikely that cyt c' is a terminal oxidase. Thus cyt c' probably functions as an electron transfer protein. The 3D structures of a number of cyt c' have been determined which show that the proteins usually exist as a dimer. The Chromatium vinosum cyt c' exhibits dimer dissociation upon ligand binding.
Patellamide A is a peptide natural product produced by Prochloron didemni, a cyanobacterial symbiont of Lissoclinum patella, and was first isolated in 1981. Patellamide A is one of many didemnid peptides. Other closely related peptides include patellamides B, C, and D and trunkamide. The patellamides and trunkamide show moderate cytotoxicity and activity against multidrug resistant cancer cell lines.
Sources: en.wikipedia.org
It has also been calculated that oganesson, unlike the other noble gases, binds an electron with release of energy, or in other words, it exhibits positive electron affinity, due to the relativistically stabilized 8s energy level and the destabilized 7p3/2 level, whereas copernicium and flerovium are predicted to have no electron affinity. Nevertheless, quantum electrodynamic corrections have been shown to be quite significant in reducing this affinity by decreasing the binding in the anion Og− by 9%, thus confirming the importance of these corrections in superheavy elements. 2022 calculations expect the electron affinity of oganesson to be 0.080(6) eV. Monte Carlo simulations of oganesson's molecular dynamics predict it has a melting point of 325±15 K and a boiling point of 450±10 K due to relativistic effects (if these effects are ignored, oganesson would melt at ≈220 K). Thus oganesson would probably be a solid rather than a gas under standard conditions, though still with a rather low melting point. Oganesson is expected to have an extremely broad polarizability, almost double that of radon. Because of its tremendous polarizability, oganesson is expected to have an anomalously low first ionization energy of about 860 kJ/mol, similar to that of cadmium and less than those of iridium, platinum, and gold. This is significantly smaller than the values predicted for darmstadtium, roentgenium, and copernicium, although it is greater than that predicted for flerovium. Its second ionization energy should be around 1560 kJ/mol.
Direct adrenergic agents such as epinephrine, norepinephrine, phenylephrine, isoproterenol, and dobutamine may be used when clinically necessary, but reduced initial doses and careful monitoring are advised because of possible potentiation. Phenelzine has also been linked to reduced vitamin B6 levels and pyridoxine deficiency. Modern guidance considers pyridoxine hydrochloride supplementation advisable with phenelzine, either from the start of treatment or if related adverse effects appear, according to clinician preference, and specifically recommends it when paresthesia or peripheral neuropathy occurs. Transaminases such as GABA-transaminase have been shown to be dependent upon vitamin B6 and may be involved in a potentially related process, since the phenelzine metabolite phenylethylidenehydrazine (PEH) is a GABA-transaminase inhibitor. Both phenelzine and vitamin B6 are rendered inactive upon these reactions occurring. The pyridoxine form of B6 is generally preferred for supplementation in this context, since this form has been shown to reduce hydrazine toxicity from phenelzine and, in contrast, the pyridoxal form has been shown to increase the toxicity of hydrazines.
It was the country's only NGO specializing in media issues, Internet access, and media monitoring during election campaigns. It had operated without government approval, and had monitored violations of journalists' rights and had taken up the cause of the ban on the dissemination of many newspapers and magazines. Ba'athist Syrian security forces arrested and beat up protestors on 15 June 2020. The protest started on 7 June 2020, in front of the governorate center against government's failure of handling economic downfall, deteriorating living conditions and corruption. HRW appealed the Syrian authority to release the peacefully protesting detainees. Pro-regime journalists who were allowed to report within the country were arrested by security forces over social media posts or ambiguous charges like being "out of line".
=== Nervous system regeneration === Because of their implications in cellular motility and shape, Rho proteins became a clear target in the study of the growth cones that form during axonal generation and regeneration in the nervous system. Rho proteins may be a potential target for delivery into spinal cord lesions after traumatic injury. Following injury to the spinal cord, the extracellular space becomes inhibitory to the natural efforts neurons undergo to regenerate. These natural efforts include the formation of a growth cone at the proximal end of an injured axon. Newly formed growth cones subsequently attempt to "crawl" across the lesion. These are sensitive to chemical cues in the extracellular environment. One of the many inhibitory cues includes chondroitin sulfate proteoglycans (CSPGs). Neurons growing in culture become more able to cross regions of substrate coated with CSPG after expression of constitutively active Cdc42 or Rac1 or expression of a dominant negative form (inhibition) of RhoA. This is partly due to the exogenous Rho proteins driving cellular locomotion despite the extracellular cues promoting apoptosis and growth cone collapse. Intracellular modulation of Rho proteins has thus become of interest in research aimed at spinal cord regeneration.
Whether or not these largely theoretical relationships are causal in humans at realistic exposure levels remains to be seen. Third-hand smoke has also been tested in various cell assays. THS exposure by cells has been shown to lead to the observation of DNA strand breaks, inhibition of proliferation, and cell death. Acrolein has shown to be a particularly potent third-hand smoke gas. A study led by Ashley Merianos, a tobacco researcher at the University of Cincinnati, revealed that in homes where children live, surfaces were contaminated with nicotine and the tobacco-specific carcinogen NNK. This was observed even in homes with voluntary indoor smoking bans, highlighting the persistent nature of THS pollutants. The study revealed higher levels of NNK and nicotine in lower-income households and homes that do not ban indoor smoking. Residential field studies have found that third-hand smoke accumulates in smokers' homes and remains even after the smokers move out, including after long periods of vacancy and standard cleaning. Nonsmoking adults and children who move into such homes have been observed to have higher nicotine levels on their hands and higher urinary cotinine than residents of homes with no history of smoking, indicating continued exposure to THS from contaminated dust, air and surfaces.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.